Previous 10 | Next 10 |
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today anno...
BMEZ was one of the best performing funds in 2020, the year it launched as it hit the market at the right time. This success did not carry over to 2021, as it was one of the seemingly few funds to produce losses for the year. It has been an even tougher go as we enter into 2022, a...
BRISBANE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophtha...
No biotech investor likes when a large percentage of patients walk away from an important clinical trial. After Annexon (NASDAQ: ANNX) revealed that this occurred in an otherwise encouraging study of its ANX005, a pipeline drug aimed at treating Huntington's disease, the company's s...
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and 75% of Evaluable Patients with Excess Baseline Complement Activity NfL Lev...
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today annou...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group (NASDAQ:QLI) -4%...
BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced s...
Shares of Annexon (ANNX +15.2%) are higher today after H.C. Wainwright initiated the stock with a buy rating and a $40 price target (~183% upside). Analyst Andrew Fein said that the company's focus on C1q inhibitors to treat neurodegenerative and autommiune disease offer tremendous potential....
Annexon Biosciences (NASDAQ:ANNX): Q3 GAAP EPS of -$0.93 misses by $0.06. Cash and cash equivalents and short-term investments were $271.4 million as of September 30, 2021. Press Release For further details see: Annexon Biosciences EPS misses by $0.06
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 17:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...